The CLOVERS trial is an attempt to find that sweet spot. Patients who volunteer for the study are put into one of two groups: One gets plentiful fluids; the other gets limited fluids and more medication. Unlike most research, this study lacks a control group — people who receive the typically given amounts of IV fluids and drugs — as a comparison.
"The problem is, both of those experimental ways for treating sepsis may do worse," says Dr. Michael Carome, head of the Public Citizen Health Research Group, which has lodged a complaint with federal health officials.
"There may be higher mortality rates for both groups compared to usual care," Carome says, and without a comparison group there's no way to tell.
And if people on one of these experimental treatments do better than those on the other, that doesn't mean it would be better than usual care, he says. This study can't answer that question.
Carome is also alarmed that, in certain unusual circumstances, the protocol calls for holding off on treating dangerously low blood pressure for several hours.
"No one caring for a sepsis patient would normally do that as part of usual care," he says.
The study, designed at Harvard and funded by the National Institutes of Health, went through multiple reviews by people who concluded that it didn't pose an undue risk to patients.
"But the fact that it got through these layers of review with these serious design flaws signals that our system for protecting human subjects is broken," Carome says.
Coopersmith, who is not involved with the CLOVERS study, reviewed Public Citizen's complaint at NPR's request. He doesn't share Carome's sense of alarm.
Coopersmith agrees that including a comparison group that received the standard of care would be a better study design.
But, "there's no clear standard of care for the first 24 hours," he says. Standard protocols for sepsis treatment dictate what doctors should do during the first six hours of treatment only, whereas the CLOVERS study is guiding treatment over a longer time period.
He says he agrees with Carome that the study won't clearly show that one of these experimental treatments is better than a more middle-of-the road approach to fluids and blood pressure medication; so sepsis doctors won't get clear guidance from the results. But the findings might help nudge doctors in one direction or another, he says, if it helps resolve the question of what's better — limited fluids or a lot?
As for the concerns about how to deal with a patient with very low blood pressure, Coopersmith says, "in a very narrow patient population for a narrow period of time, there is a theoretical chance that someone could have what I would consider to be too low a blood pressure."
If he were a doctor involved in this trial and encountered that, he says, he would deviate from the protocol and treat that patient with standard care. He expects his colleagues would do that as well.
The study isn't designed the way he would have done it, Coopersmith says, but, he "would be comfortable enrolling patients in this trial."
Dr. Nathan Shapiro, a professor of Emergency Medicine at Harvard's Beth Israel Deaconess Medical Center and one of the principal investigators for the CLOVERS study, stands by it. He declined a request for an interview, but sent a written response to NPR.
"The study protocol was designed by expert clinicians in emergency and critical care medicine representing nearly 50 hospitals in the United States and follows a well-accepted design," he writes.
A spokesperson for the federal Office for Human Research Protections says the office has not yet seen the Public Citizen complaint, but will review the allegations.
Richard Harris can be reached at email@example.com.
Copyright 2018 NPR. To see more, visit http://www.npr.org/.